Nelarabine

Jul 27, 2017 by in ONCOLOGY Comments Off on Nelarabine

Fig. 14.1 The chemical structures of nelarabine and ara-G. (a) Nelarabine. (b) Ara-G 14.2 Mechanisms of Action 14.2.1 Mechanisms of Action (Fig. 14.2) In the blood, nelarabine is rapidly demethoxylated…

read more

Therapies Targeting Leukemic Stem Cells

Jul 27, 2017 by in ONCOLOGY Comments Off on Therapies Targeting Leukemic Stem Cells

Fig. 20.1 Various causes of LSC development In recent years, new techniques have begun to revolutionize the diagnosis, prognosis, and classification of leukemia. More recently, the introduction of high-speed analysis…

read more

Epigenetic Regulator, Re-emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results

Jul 27, 2017 by in ONCOLOGY Comments Off on Epigenetic Regulator, Re-emerging Antimetabolites with Novel Mechanism of Action (Azacitidine and Decitabine): Clinical Pharmacology and Therapeutic Results

  Aza C Supportive care Crossover No. of patients  % No. of patients  % No. of patients  % No. evaluated  99   92   49  CR 7  7* 0  0 5  10…

read more

Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results

Jul 27, 2017 by in ONCOLOGY Comments Off on Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results

Fig. 6.1 Treatment strategy of B-CLL by the GCLLSG. Abbreviations: FCR fludarabine, cyclophosphamide, and rituximab, BR bendamustine and rituximab, R-idelalisib rituximab and idelalisib, SCT stem cell transplantation, G-CLB obinutuzumab and…

read more
Premium Wordpress Themes by UFO Themes